ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Syndax Pharmaceuticals, Inc. ?
1
Poor Management Efficiency with a low ROE of 0.83%
- The company has been able to generate a Return on Equity (avg) of 0.83% signifying low profitability per unit of shareholders funds
2
With a growth in Net Sales of 91.76%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -220.64 MM
- NET PROFIT(HY) Higher at USD -92.04 MM
- DEBTORS TURNOVER RATIO(HY) Highest at 4.58 times
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 60.38%, its profits have risen by 10.5%
4
Rising Promoter Confidence
- Promoters have increased their stake in the company by 3.15% over the previous quarter and currently hold 9.89% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
5
Market Beating Performance
- The stock has generated a return of 60.38% in the last 1 year, much higher than market (S&P 500) returns of 22.36%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Syndax Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Syndax Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Syndax Pharmaceuticals, Inc.
60.38%
0.06
54.43%
S&P 500
22.36%
1.70
13.18%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
157.66%
EBIT Growth (5y)
-212.73%
EBIT to Interest (avg)
-75.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.78
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.83%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
32.06
EV to EBIT
-7.41
EV to EBITDA
-7.41
EV to Capital Employed
135.34
EV to Sales
11.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1826.10%
ROE (Latest)
-441.62%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend20What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -220.64 MM
NET PROFIT(HY)
Higher at USD -92.04 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 4.58 times
RAW MATERIAL COST(Y)
Fallen by 1.09% (YoY
NET SALES(Q)
Highest at USD 72.79 MM
-10What is not working for the Company
ROCE(HY)
Lowest at -255.93%
DEBT-EQUITY RATIO
(HY)
Highest at 275 %
INTEREST(Q)
Highest at USD 12.68 MM
Here's what is working for Syndax Pharmaceuticals, Inc.
Net Sales
At USD 72.79 MM has Grown at 91.76%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -92.04 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 4.58 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Operating Cash Flow
Highest at USD -220.64 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 72.79 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Raw Material Cost
Fallen by 1.09% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Syndax Pharmaceuticals, Inc.
Interest
Highest at USD 12.68 MM
in the last five periods and Increased by 7.01% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at 275 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
